加载中
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
前收盘价
US$15.53
+US$0.07 · +0.45%
盘前
US$15.56
+US$0.03 · +0.19%
10月12日 8:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日内区间
当前US$15.53
52周区间
当前US$15.53
盘中时间采用ET。市场数据可能有所延迟。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日内区间
当前US$15.53
52周区间
当前US$15.53
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 1894.3万 USD |
| 销货成本 | — | 30.6万 USD | — | — | — |
| 毛利 | — | −30.6万 USD | — | — | 1894.3万 USD |
| 研究与开发 | 1.87亿 USD | 1.43亿 USD | 1.48亿 USD | 9194.8万 USD | 5775.1万 USD |
| 销售、一般及管理费用 | 5424.6万 USD | 5371万 USD | 4249.3万 USD | 4018.9万 USD | 2914.6万 USD |
| 营业费用 | 2.42亿 USD | 1.97亿 USD | 1.91亿 USD | −1.45亿 USD | 8689.7万 USD |
| 利息收入 | 2221.2万 USD | 2966万 USD | 2162.7万 USD | 661.1万 USD | 47.7万 USD |
| 折旧和摊销 | 31.1万 USD | 30.6万 USD | 31万 USD | 9.3万 USD | 5.3万 USD |
| 营业利润 | −2.42亿 USD | −1.97亿 USD | −1.91亿 USD | 1.45亿 USD | −6795.4万 USD |
| 净利润 | −2.2亿 USD | −1.67亿 USD | −1.53亿 USD | 1.11亿 USD | −6557万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$34.75
上涨空间 123.76%价格历史记录不可用
最高：US$40.00平均的：US$34.75最低：US$27.00报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4314.01万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2468.24万0.03%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1921.5万0.19%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1373.86万0.01%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO767.77万0.04%180亿 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB564.22万0.05%108.2亿 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS528.85万0.02%338.69亿 USD0.31%US$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM480.31万0.07%64.1亿 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
